Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Infliximab for the Treatment of Moderate-to-Severe Psoriasis: Response to Retreatment

Infliximab for the Treatment of Moderate-to-Severe Psoriasis: Response to Retreatment. 15th Congress of the European Academy of Dermatology and Venereology, Rhodes, Greece. 2006.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.